Smith James M, Amara Rama Rao, Wyatt Linda S, Ellenberger Dennis L, Li Bin, Herndon James G, Patel Milloni, Sharma Sunita, Chennareddi Lakshmi, Butera Sal, McNicholl Janet, McClure Harold M, Moss Bernard, Robinson Harriet L
Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30329, USA.
AIDS Res Hum Retroviruses. 2005 Feb;21(2):140-4. doi: 10.1089/aid.2005.21.140.
One of the unknowns faced by an HIV/AIDS vaccine is the ability of a single clade vaccine to protect against the multiple genetic subtypes and recombinant forms of HIV-1 present in the current pandemic. Here, we use a macaque model to investigate the ability of our clade B vaccine that consists of DNA priming and modified vaccinia Ankara (MVA) virus boosting to elicit T cell responses that recognize an A/G recombinant of HIV-1. To test for cross-reactive T cells, intracellular cytokine staining was conducted using five pools of Gag and six pools of Env peptides representing B or A/G sequences. Studies using the peptide pools revealed essentially complete conservation of the CD8 response but only approximately 50% conservation of the CD4 response. Thus, the ability of an HIV vaccine for one clade to protect against other clades may be more limited by the ability to provide CD4 T cell help than the ability to elicit CD8 effector functions.
艾滋病疫苗面临的未知问题之一是，单一分支疫苗能否抵御当前大流行中存在的多种HIV-1基因亚型和重组形式。在此，我们使用猕猴模型来研究我们的B分支疫苗（由DNA初免和改良安卡拉痘苗病毒（MVA）加强免疫组成）引发识别HIV-1 A/G重组体的T细胞反应的能力。为了检测交叉反应性T细胞，使用代表B或A/G序列的5组Gag肽和6组Env肽进行细胞内细胞因子染色。使用肽池的研究显示，CD8反应基本完全保守，但CD4反应仅约50%保守。因此，一种HIV疫苗针对一个分支的保护能力，在抵御其他分支时，可能更多地受到提供CD4 T细胞辅助能力的限制，而非引发CD8效应功能的能力。
